The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates

Multiple Sclerosis

Volumn 23, Issue 2, 2017, Pages 228-233

  Hamid, Shahd H M ^a   Elsone, Liene ^a   Mutch, Kerry ^a   Solomon, Tom ^a,b   Jacob, Anu ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

central nervous system demyelination; criteria; multiple sclerosis; Neuromyelitis optica spectrum disorders

Indexed keywords

AQUAPORIN 4; IMMUNOGLOBULIN G; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; AQP4 PROTEIN, HUMAN; AUTOANTIBODY;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENGLAND; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROLOGIC DISEASE ASSESSMENT; OPTIC NEURITIS; RECURRENT DISEASE; CENTRAL NERVOUS SYSTEM; IMMUNOLOGY; METABOLISM;

AQUAPORIN 4; AUTOANTIBODIES; CENTRAL NERVOUS SYSTEM; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; NEUROMYELITIS OPTICA;

EID: 85011931048     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458516663853     Document Type: Article

References (17)

1. Jacob A, Larner AJ,. Clifford Allbutt (1836-1925). J Neurol 2013; 260: 346-347.
2. Devic E,. Myélite subaiguë compliquée de névrite optique. Bull Med 1894; 8: 1033-1034.
3. Cree BA, Goodin DS, Hauser SL,. Neuromyelitis optica. Semin Neurol 2002; 22: 105-122.
4. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
5. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
6. Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology 2015; 84: 1165-1173.
7. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
8. Sato DK, Nakashima I, Takahashi T, et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 2013; 80: 2210-2216.
9. Probstel AK, Rudolf G, Dornmair K, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation 2015; 12: 46.
10. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
11. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology 2012; 78: 665-671.
12. Jurynczyk M, Weinshenker B, Akman-Demir G, et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol 2016; 263: 140-149.
13. Reindl M, Rostasy K,. MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm 2015; 2: e60.
14. Zamvil SS, Slavin AJ,. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015; 2: e62.
15. Palace J, Leite MI, Jacob A,. A practical guide to the treatment of neuromyelitis optica. Pract Neurol 2012; 12: 209-214.
16. Hyun JW, Jeong IH, Joung A, et al. Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. Neurology 2016; 86: 1772-1779.
17. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: Review and recommendations. Mult Scler Relat Disord 2012; 1: 180-187.